GGrantIndex
← Leaderboards

David E. Williams

Oregon State University

$14,401,927
Attributed
$14,401,927
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.1M · FY200522
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$31,806,405 · 12

By mechanism

P42$17,999,030 · 4
R01$8,018,015 · 3
T32$2,409,203 · 1
P30$2,127,828 · 1
P01$1,208,047 · 1
T35$30,282 · 1

Top collaborators

No co-investigators on record.

Most similar at Oregon State University

Same institution · by research overlap

Others in their field

Top investigators on “Research Personnel

Research focus

Research PersonnelLaboratoriesAromatic Polycyclic HydrocarbonsToxic EffectProgramsGrantRisk AssessmentInnovationNew TechnologyGeneral PopulationSuperfund SiteExposure ToEnvironmentUniversitiesOregonMetabolismTechnologyCarcinogenesisDosePacific NorthwestBaseResponseEnvironmental HealthExhibits

Grant awards (72)

Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention$460,228
R01 · FY2022 · ES · contact PI
Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention$460,235
R01 · FY2021 · ES · contact PI
Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention$503,436
R01 · FY2020 · ES · contact PI
Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention$503,711
R01 · FY2019 · ES · contact PI
Core A: Administrative Core$397,097
P42 · FY2019 · ES · contact PI
Benzo[a]pyrene Micro-dosing of Humans: A New Tool for Exposure, Risk Assessment and Prevention$580,890
R01 · FY2018 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$289,744
P42 · FY2017 · ES · contact PI
Core A: Administrative Core$74,012
P42 · FY2017 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$283,829
P42 · FY2016 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$88,347
P42 · FY2016 · ES · contact PI
Core A: Administrative Core$72,502
P42 · FY2016 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$295,652
P42 · FY2015 · ES · contact PI
Core A: Administrative Core$75,522
P42 · FY2015 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$291,895
P42 · FY2014 · ES · contact PI
Transplacental Chemoprevention of Lung Tumors and Lymphomas$260,425
P01 · FY2014 · CA · contact PI
Core A: Administrative Core$72,830
P42 · FY2014 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$10,800
P42 · FY2014 · ES · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$983
P42 · FY2014 · ES · contact PI
Core A: Administrative Core$982
P42 · FY2014 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$3,117,308
P42 · FY2013 · ES · contact PI
Flavin-Containing Monooxygenase in Lung$331,109
R01 · FY2013 · HL · contact PI
Project 1: PAHs in Humans at Environmental Levels Pharmacokinetics, Metabolism a$295,652
P42 · FY2013 · ES · contact PI
Transplacental Chemoprevention of Lung Tumors and Lymphomas$216,948
P01 · FY2013 · CA · contact PI
Core A: Administrative Core$87,022
P42 · FY2013 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$10,800
P42 · FY2013 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$10,800
P42 · FY2013 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$2,888,367
P42 · FY2012 · ES · contact PI
Flavin-Containing Monooxygenase in Lung$347,804
R01 · FY2012 · HL · contact PI
Transplacental Chemoprevention of Lung Tumors and Lymphomas$216,317
P01 · FY2012 · CA · contact PI
Core A: Administrative Core$115,702
P42 · FY2012 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$10,800
P42 · FY2012 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$2,910,352
P42 · FY2011 · ES · contact PI
Flavin-Containing Monooxygenase in Lung$359,770
R01 · FY2011 · HL · contact PI
Transplacental Chemoprevention of Lung Tumors and Lymphomas$287,188
P01 · FY2011 · CA · contact PI
Core A: Administrative Core$115,178
P42 · FY2011 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$2,977,073
P42 · FY2010 · ES · contact PI
Flavin-Containing Monooxygenase in Lung$338,818
R01 · FY2010 · HL · contact PI
Transplacental Chemoprevention of Lung Tumors and Lymphomas$227,169
P01 · FY2010 · CA · contact PI
PAHs: New Technologies and Emerging Health Risks$49,050
P42 · FY2010 · ES · contact PI
Core A: Administrative Core$45,936
P42 · FY2010 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$20,000
P42 · FY2010 · ES · contact PI
The 5th Aquatic Animal Models for Human Disease Conference$14,000
R13 · FY2010 · RR · contact PI
PAHs: New Technologies and Emerging Health Risks$3,035,716
P42 · FY2009 · ES · contact PI
PAHs: New Technologies and Emerging Health Risks$235,584
P42 · FY2009 · ES · contact PI
Core A: Administrative Core$119,495
P42 · FY2009 · ES · contact PI
Ultra-Low Dose Carcinogen Testing with the Trout Model$108,720
R01 · FY2009 · ES · contact PI
Ultra-Low Dose Carcinogen Testing with the Trout Model$434,603
R01 · FY2008 · ES · contact PI
Flavin-containing Monooxygenase in Lung$282,472
R01 · FY2008 · HL · contact PI
Ultra-Low Dose Carcinogen Testing with the Trout Model$493,573
R01 · FY2007 · ES · contact PI
Flavin-containing Monooxygenase in Lung$282,732
R01 · FY2007 · HL · contact PI
Ultra-Low Dose Carcinogen Testing with the Trout Model$501,768
R01 · FY2006 · ES · contact PI
Marine and Freshwater Biomedical Sciences Center$422,645
P30 · FY2006 · ES · contact PI
Flavin-containing Monooxygenase in Lung$291,429
R01 · FY2006 · HL · contact PI
Ultra-Low Dose Carcinogen Testing with the Trout Model$429,453
R01 · FY2005 · ES
Marine and Freshwater Biomedical Sciences Center$422,683
P30 · FY2005 · ES
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$420,992
T32 · FY2005 · ES
Flavin-containing Monooxygenase in Lung$309,059
R01 · FY2005 · HL
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$435,643
T32 · FY2004 · ES
Marine and Freshwater Biomedical Sciences Center$424,500
P30 · FY2004 · ES
Flavin-Containing Monooxygenase in Lung$250,250
R01 · FY2004 · HL
MARINE &FRESHWATER BIOMEDICAL SCIENCES CENTER GRANT$429,000
P30 · FY2003 · ES
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$427,560
T32 · FY2003 · ES
Flavin-Containing Monooxygenase in Lung$250,250
R01 · FY2003 · HL
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$404,573
T32 · FY2002 · ES
MARINE &FRESHWATER BIOMEDICAL SCIENCES CENTER GRANT$357,500
P30 · FY2002 · ES
Flavin-Containing Monooxygenase in Lung$250,250
R01 · FY2002 · HL
MARINE &FRESHWATER BIOMEDICAL SCIENCES CENTER GRANT$71,500
P30 · FY2002 · ES
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$378,752
T32 · FY2001 · ES
Flavin-Containing Monooxygenase in Lung$247,455
R01 · FY2001 · HL
SHORT-TERM RESEARCH TRAINING FOR MINORITY STUDENTS$16,351
T35 · FY2001 · ES
MODE OF ACTION OF ENVIRONMENTAL TOXICANTS$341,683
T32 · FY2000 · ES
SHORT-TERM RESEARCH TRAINING FOR MINORITY STUDENTS$13,931
T35 · FY2000 · ES